Maternal and Child Health Federal Consolidated Programs

 

The Special Projects of Regional and National Significance Program (SPRANS) carries out maternal and child health (MCH) projects to support training and research; oral health integration; genetic disease testing, counseling, and information development and dissemination programs; newborn screening for sickle cell anemia and other genetic disorders; and comprehensive hemophilia diagnostic and treatment centers. The Community Integrated Service Systems program works to develop and expand home visitation; participation of obstetricians and pediatricians; integrated service delivery systems; maternal and child health centers; services for rural populations; and integrated state and community service systems for children and youth with special health care needs. The Heritable Disorders Program serves to improve the ability of States 1) to provide newborn and child screening for heritable disorders and 2) to expand screenings as the capacity to screen for genetic and congenital conditions expands. Newborn and child screenings occur at intervals across the life span of every child. Newborn screening universally provides early identification and follow-up for treatment of infants affected by certain genetic, metabolic, hormonal and/or functional conditions. The Supporting Fetal Alcohol Spectrum Disorder (FASD) Screening and Intervention program trains primary care providers to reduce the incidence of prenatal alcohol exposure and improve developmental outcomes in children with suspected or diagnosed FASDs. The program reaches providers in states, territories, tribes, or communities that have high rates of binge drinking among pregnant women, especially in rural areas. The Screening and Treatment for Maternal Mental Health and Substance Use Disorders (MMHSUD) program helps address maternal mental health conditions that affect women during and after pregnancy by expanding health care providers capacity to screen, assess, treat, and refer pregnant and postpartum people for maternal depression and related behavioral disorders. The Pediatric Mental Health Care Access (PMHCA) program promotes behavioral health integration in pediatric primary care by developing new or expanding existing statewide or regional pediatric mental health care telehealth access programs that help these and other providers diagnose, treat, and refer children with behavioral health conditions. PMHCA works to address the shortages of psychiatrists, developmental-behavioral pediatricians, and other behavioral health clinicians to support children and adolescents with behavioral concerns. The Integrated Maternal Health Services program fosters the development and demonstration of integrated maternal health services models, such as the Maternity Medical Home, which is modeled after the patient-centered medical home. The models developed and demonstrated support comprehensive care for pregnant and postpartum people who experience health disparities and have limited access to basic social and health care services. The Alliance for Innovation on Maternal Health (AIM) program promotes safety and quality of care during and immediately after childbirth and addresses the high rates of maternal morbidity and mortality in the U.S. It is the national, cross-sector commitment designed to lead in the identification, development, implementation, and dissemination of maternal (patient) safety bundles for the promotion of safe care for every U.S. birth. The AIM Technical Assistance Center supports all entities participating in the AIM program to increase birthing facility engagement, support bundle implementation and sustainability, manage reporting and analysis of state AIM data, and promote safe care for pregnant and postpartum people. The purpose of State Maternal Health Innovation program is to reduce maternal mortality and severe maternal morbidity by supporting state-led demonstrations focused on improving maternal health and addressing maternal health disparities through quality services, a skilled workforce, enhanced data quality and capacity, and innovative programming. The MCH Research Portfolio includes the MCH Research Network (MCH RN), MCH Field-Initiated Innovative Research Studies (MCH FIRST), and MCH Secondary Data Analysis (MCH SDAR) Programs. MCH RNs focus on collaborative, interdisciplinary, multisite research forums and dissemination of information to build infrastructure. The networks provide national leadership in research to advance the evidence base on effective interventions for mothers, children, and families. The MCH FIRST and MCH SDAR Programs support investigator-initiated applied MCH research that has the potential to improve health care services and delivery, and to promote the health and wellbeing of maternal and child populations. MCH FIRST grants involve the collection of original data. MCH SDAR grants focus exclusively on secondary analyses of existing national or other large-scale data sets.

Active 93.110 Health Resources and Services Administration, Department of Health and Human Services B - Project Grants Fiscal Year 2020 In FY 2019, the Leadership Education in Adolescent Health (LEAH) program provided interdisciplinary leadership training to 2,197 health and related professionals at the graduate and postgraduate levels; enhanced the knowledge and skills of nearly 30,000 practicing professionals through the provision of 538 continuing education events; and strengthened the capacity of Title V and other MCH partners through 650 technical assistance activities to 136,660 recipients in local, state, and community entities. In FY 2020, the Strengthen the Evidence in Maternal and Child Health Program provided 44 technical assistance (TA) sessions to states and jurisdictions, including several regional TA sessions, topic-specific TA, and TA to all Pacific Basin and Atlantic jurisdictions; worked extensively with a team of expert reviewers to publish two Evidence Analysis Reports, for updates of National Performance Measure (NPM) Online Toolkits, and for TA requests; engaged 16 experts in the webinar development of evidence-based, informed strategies for the 15 Title V national performance measures, made available to all Title V states and jurisdictions’. The heritable disorders program has supported the widespread adoption of SCID newborn screening since 2014. In 2012, only six states screened for SCID. By 2018, all 50 states and 3 U.S. territories screen for SCID. Despite the success of broad SCID newborn screening, gaps remain in optimizing outcomes for infants with SCID that is detected by newborn screening. Additionally, almost 50% of states have implemented the four new conditions (Pompe [2015], X-ALD [2016], MPS I [2016], and SMA [2018]) added to the recommended screening panel since 2015.
Fiscal Year 2021 The Heritable Disorders Program has supported the widespread adoption of newborn screening since 2008. For example, in 2012, only six states screened for severe combined immunodeficiency (SCID). By 2018, all 50 states and 3 U.S. territories screen for SCID. Additionally, more than 50% of states have implemented four new conditions added to the recommended screening panel since 2013, including Pompe disease, X-linked adrenoleukodystrophy, Mucopolysaccharidosis type I, and Spinal Muscular Atrophy. Screening and Treatment for Maternal Depression and Related Behavioral Disorders programs improved short- and intermediate-term outcomes in training, consultation, and screening services. Awardees trained 1,085 providers in FY 2020, an increase from 160 providers trained in FY 2019. Providers received expert consultation for 7,448 pregnant and postpartum women in FY 2020, of which 47% lived in rural/underserved areas, an increase from 233 pregnant and postpartum women in FY 2019, of which 30% lived in rural/underserved areas. The number of pregnant and postpartum women screened for depression by participating providers increased from 4,053 in FY 2019 to 24,518 in FY 2021. In FY 2021, the Supporting Fetal Alcohol Spectrum Disorder Screening and Intervention Program enrolled 10 prenatal and 12 pediatric practices within 14 health centers in seven states in their 10-month Project Echo training program. Five of the enrolled health centers serve rural, 9 serve urban, and 3 serve tribal communities. At the mid-point survey, a high proportion of participants reported: increased knowledge about screening for Prenatal Alcohol Exposure (PAE) both during pregnancy and among children with possible FASD; improved self-efficacy to screen for PAE and counsel families about both PAE and FASD; and increased practice of screening for, and counseling patients with alcohol use during pregnancy and screening for PAE among children with suspected FASD.
Fiscal Year 2022 The Heritable Disorders Program has supported the widespread adoption of newborn screening since 2008. For example, in 2012, only six states screened for severe combined immunodeficiency (SCID). By 2018, all 50 states and 3 U.S. territories screen for SCID. Currently, all states screen for at least 31 core conditions on the Recommended Uniform Screening Panel (RUSP). Across the U.S., 40 out of 53 state newborn screening programs screen for 90% or more of the core conditions on the RUSP. . The MMHSUD program improved short- and intermediate-term outcomes in training, consultation, and screening services. Awardees trained 1,875 providers in FY 2022 compared to 782 in FY 2021. The number of providers using the MMHSUD program for consultation and care coordination support services for treatment and referral of pregnant and postpartum women with behavioral health conditions increased from 584 in FY 2021 to 824 in FY 2022. In FY 2022, the FASD Screening and Intervention program completed their first learning collaborative cohort which included 10 prenatal and 12 pediatric practices within 14 health centers in 7 states. The program also enrolled their second cohort which included 11 prenatal and 11 pediatric practices within 16 health centers in seven states. The combined cohorts included health centers serving 9 rural, 21 urban, and 7 tribal communities. Participants from the first cohort reported increased knowledge about screening for Prenatal Alcohol Exposure (PAE) both during pregnancy and among children with possible FASD; improved self-efficacy to screen for PAE and counsel families about both PAE and FASD; and increased practice of screening for, and counseling patients with alcohol use during pregnancy and screening for PAE among children with suspected FASD. Birthing facilities in all 50 states and D.C. are implementing AIM patient safety bundles (PSBs). As of February 2023, there are: • 1,917 birthing facilities participating in AIM. • 25 states engaged in widespread implementation of AIM PSBs • 7 states are implementing targeted quality improvement projects • 29 states implementing the Obstetric Hemorrhage bundle • 34 implementing the Severe Hypertension in Pregnancy bundle, and • 27 states implementing the Care for Pregnant and Postpartum People with Substance Use Disorder bundle. In June 2023, AIM launched the Obstetric Emergency Readiness Resource Kit, for use by teams in healthcare settings that may not typically provide obstetric services or frequently care for people experiencing obstetric emergencies. Since 2019, the State Maternal Health Innovation awardees have established Maternal Health Task Forces that regularly convene multidisciplinary stakeholders; created and are implementing a strategic plan that incorporates activities from the state’s most recent Title V Needs Assessment; and reported state-level data surveillance on maternal mortality and severe maternal morbidity for three years in their Maternal Health Annual Reports. Across 21 states in FY 2021, the PMHCA program achieved the following: • Over 6,700 primary care providers enrolled in a statewide or regional PMHCA program. • Over 2,000 providers used consultation and care coordination support services • Over 8,200 children and adolescents were served by Pediatric primary care providers who contacted the pediatric mental health team. Accomplishments from the MCH Research Networks in FY 2021 include: • Completed 104 studies on a broad range of maternal, child, and family health topics • Enrolled 13,998 participants in primary research studies across 475 research sites across the country, and included 2,822,373 participants in secondary data analyses • Published 75 peer-reviewed manuscripts in leading scholarly journals Social Security Act, Title V, Section 502(a)(1) and (b)(1), as amended; 42 U.S.C. 702.; Sections 1109, 1110, 1111 and 1112 of the Public Health Service Act and Section 399T of the Public Health Service Act; Public Health Service Act, § 330M (42 U.S.C. § 254c-19), as amended.42 U.S.C. 254c-21 (Public Health Service Act, Title III Section 330O) ; 42 U.S.C. § 701(a)(2) (Title V, § 501(a)(2) of the Social Security Act) Training grants may be made to public or private nonprofit institutions of higher learning. Research grants may be made to public or private nonprofit institutions of higher learning and public or private nonprofit private agencies and organizations engaged in research or in MCH or Children with Special Health Care Needs (CSHCN) programs. Any public or private entity is eligible for hemophilia, genetics, and environmental health grants and other special project grants, including SPRANS and CISS. Eligible entities for the Heritable Disorders Program include a State or a political subdivision of a State; a consortium of two or more States of political subdivisions of States; a territory; a health facility or program operated by or pursuant to a contract with or grant from the Indian Health Service; or any other entity with appropriate expertise in newborn screening, as determined by the Secretary. Eligible entities for the Pediatric Mental Health Care Access Program include States, political subdivisions of states, and Indian tribes and tribal organizations. Eligible entities for the Screening and Treatment for Maternal Depression and Related Behavior Disorders Program are states. Eligible entities for the Supporting Fetal Alcohol Spectrum Disorders Screening and Intervention program are any domestic public or private entity, including Indian tribes or tribal organizations (as those terms are defined at 25 U.S.C. 450b). See 42 CFR ? 51a.3(a), and domestic faith-based and community-based organizations. Eligible entities for the Alliance for Innovation on Maternal Health (AIM) program include any domestic public or private entity, including domestic faith-based and community-based organizations, tribes, and tribal organizations. Eligible entities for the State Maternal Health Innovation program include any domestic public or private entity, including Indian tribes or tribal organizations, as well as domestic faith-based and community-based organizations. Eligible entities for the Integrated Maternal Health Services program include any domestic public or private entity, including Indian tribes or tribal organizations, as well as domestic faith-based and community-based organizations. For training grants: (1) Trainees in the health professions related to MCH; and (2) mothers and children who receive services through training programs. For research grants: public or private nonprofit agencies and organizations engaged in research in MCH or CSHCN programs. For hemophilia, sickle cell, thalassemia, genetics, newborn screening, environmental health, and other special projects: (1) Public or private agencies, organizations and institutions; and (2) mothers and children, and individuals with genetic conditions (any age) who receive services through the programs. For Pediatric Mental Health Care Access Program: pediatric mental health care teams; pediatric primary care providers; children, youth and families who receive services from pediatric primary care providers. Applicants should review the individual HRSA notice of funding opportunity issued under this Assistance Listing for any required proof or certifications which must be submitted prior to or simultaneous with submission of an application package. Preapplication coordination is required. This program is eligible for coverage under E.O. 12372, "Intergovernmental Review of Federal Programs." An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review. 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. HRSA requires all applicants to apply electronically through Grants.gov. All qualified applications will be forwarded to an objective review committee. Based on the advice of the objective review committee, the HRSA program official with delegated authority is responsible for final selection and funding decisions. All qualified applications will be forwarded to an objective review committee. Based on the recommendations of the objective review committee, the HRSA program official with delegated authority is responsible for final selection and funding decisions. Notification is made in writing by a Notice of Award. Contact the headquarters or regional location, as appropriate for application deadlines From 120 to 180 days. Final decisions are made 4 to 6 months after receipt of applications. Not applicable. Competitive awards are typically made for up to 2 to 5 years, subject to the availability of funds. After initial awards, annual noncompetitive awards may be made contingent upon the submission of noncompetitive applications/progress reports and availability of funds and a determination that continued funding would be in the best interest of the federal government. Evaluation criteria vary based on the grant/cooperative agreement program. Refer to criteria included in the notice of funding opportunity for each specific program. Training grants are made to institutions of higher learning for training personnel for health care and related services for mothers and children. Research grants are for the purpose of research activities which show promise of a substantial contribution to the advancement of maternal and child health (MCH) services. Technical assistance grants support the effective and accurate use of data and evidence to support program development and implementation as well as performance measurement and evaluation. Genetic grants are for genetic disease testing, counseling and information development and dissemination. Hemophilia grants are for the support of centers which provide hemophilia diagnostic and treatment services. Sickle cell disease grants are made to support follow up for infants with sickle cell identified through newborn screening. Heritable Disorders grants are made to improve the ability of States to provide newborn and child screening for heritable disorders, coordinate services and long-term follow-up for newborns and children identified with a condition through newborn screening, and to provide newborn screening education resources to patients, parents, and families. Environmental health grants are made to decrease maternal and child morbidity and mortality associated with pre-and post-natal environmental exposures. Pediatric Mental Health Care Access grants promote behavioral health integration into pediatric primary care by supporting pediatric mental health care telehealth access programs. Screening and Treatment for Maternal Depression and Related Behavior Disorders expands health care providers’ capacity to screen, assess, treat, and refer pregnant and postpartum women for depression and related disorders. Other special project grants are designed to support activities of a demonstration nature, which are designed to improve services for mothers and children. Restricted Uses: Indirect costs that are allowed for administrative costs incurred as a result of the training grants project, are limited to 8 percent of direct costs. Not applicable. In accordance with the provisions of 2 CFR 200, Subpart F - Audit Requirements, nonfederal entities that expend financial assistance of $750,000 or more in Federal awards will have a single or a program-specific audit conducted for that year. Non-Federal entities that expend less than $750,000 a year in Federal awards are exempt from Federal audit requirements for that year, except as noted in 2 CFR 200.503 Grantees are required to maintain grant accounting records for 3 years after the date they submit the Federal Financial Report (FFR). If any litigation, claim, negotiation, audit, or other action involving the award has been started before the expiration of the 3-year period, the records shall be retained until completion of the action and resolution of all issues which arise from it, or until the end of the regular 3-year period, whichever is later. Statutory formula is not applicable to this assistance listing.

Matching is voluntary. Opportunities may include matching requirements. Please refer to the notice of funding opportunity.

MOE requirements are not applicable to this assistance listing. Refer to the NOFO for details. Awards are made annually, in accordance with the project period method of awarding grants. Payments are made through a Letter-of-Credit or Cash Demand System. Grantees draw down funds, as necessary, from the Payment Management System (PMS). PMS is the centralized web based payment system for HHS awards. None/Not specified. Michael D Warren, Associate Administrator for Maternal and Child Health,
5600 Fishers Lane
Rockville, MD 20857 US
MWarren@hrsa.gov
Phone: 301-443-2170 http://www.hrsa.gov 75-0354-0-1-550 (Project Grants) FY 22$72,073,211.00; FY 23 est $80,944,822.00; FY 24 est $80,076,786.00; FY 21$72,656,614.00; FY 20$93,387,733.00; FY 19$72,514,735.00; FY 18$77,324,714.00; FY 17$132,166,263.00; FY 16$133,938,299.00; - Project Grants(Cooperative Agreements) FY 22$176,579,143.00; FY 23 est $275,584,617.00; FY 24 est $214,052,723.00; FY 21$127,554,105.00; FY 20$108,158,573.00; FY 19$95,189,412.00; FY 18$72,482,155.00; - Project Cooperative Agreements Project Grants FY 22 act. $364 to $734,591; $279,353 FY 23 est. $27,249 to $738,000; $283,024 FY 24 est. $27,562 to $788,466; $281,961 Project Cooperative Agreements FY 22 act. $75,000 to $9,696,361; $741,929 FY 23 est. $75,000 to $10,900,000; $1,036,032 FY 24: est. $75,000 to $10,900,000; $842,727 All HRSA awards are subject to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements at 45 CFR part 75. HRSA awards are subject to the requirements of the HHS Grants Policy Statement (HHS GPS) that are applicable based on recipient type and purpose of award. The HHS GPS is available at http://www.hrsa.gov/grants. Not applicable.